PHS Guideline for Reducing Human Immunodeficiency Virus,Hepatitis B Virus,and Hepatitis C Virus Transmission through Organ Transplantation

Rogers MF Simonds RJ Lawton KE Moseley RR Jones WK . Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. MMWR Recomm Rep 1994; 43(RR-8):1–17.

Food and Drug Administration (US). Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products. August 2007 [cited 2013 Mar 13]. Available from: URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm091345.pdf

Wolf JL Perkins HA Schreeder MT Vincenti F . The transplanted kidney as a source of hepatitis B infection. Ann Intern Med 1979; 91: 412–3.

Human immunodeficiency virus infection transmitted from an organ donor screened for HIV antibody—North Carolina. MMWR Morb Mortal Wkly Rep 1987; 36(20):306–8.

Bowen PA 2nd Lobel SA Caruana RJ Leffell MS House MA Rissing JP Transmission of human immunodeficiency virus (HIV) by transplantation: clinical aspects and time course analysis of viral antigenemia and antibody production. Ann Intern Med 1988; 108:46–8.

Simonds RJ Holmberg SD Hurwitz RL Coleman TR Bottenfield S Conley LJ Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med 1992; 326:726–32.

Simonds RJ . HIV transmission by organ and tissue transplantation. AIDS 1993; 7 Suppl 2:S35–8.

Hepatitis C virus transmission from an antibody-negative organ and tissue donor—United States, 2000–2002. MMWR Morb Mortal Wkly Rep 2003; 52(13):273–6.

Ison MG Llata E Conover CS Friedewald JJ Gerber SI Grigoryan A Transmission of human immunodeficiency virus and hepatitis C from an organ donor to four transplant recipients. Am J Transplant 2011; 11:1218–25.

Potential transmission of viral hepatitis through use of stored blood vessels as conduits in organ transplantation—Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 2011; 60(6):172–4.

HIV transmitted from a living organ donor—New York City, 2009. MMWR Morb Mortal Wkly Rep 2011; 60(10):297–301.

Notes from the field: transplant-transmitted hepatitis B virus—United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60(32):1087.

Transmission of hepatitis C virus through transplanted organs and tissue—Kentucky and Massachusetts, 2011 [published erratum appears in MMWR Morb Mortal Wkly Rep 2012;61(4):80]. MMWR Morb Mortal Wkly Rep 2011; 60(50):1697–700.

Guyatt GH Oxman AD Vist GE Kunz R Falck-Ytter Y Alonso-Coello P GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924–6.

Guyatt GH Oxman AD Kunz R Vist GE Falck-Ytter Y Schünemann HJ ; GRADE Working Group. What is “quality of evidence” and why is it important to clinicians? BMJ 2008; 336:995–8.

Guyatt GH Oxman AD Kunz R Falck-Ytter Y Vist GE Liberati A Going from evidence to recommendations. BMJ 2008; 336:1049–51.

Schünemann HJ Oxman AD Brozek J Glasziou P Jaeschke R Vist GE Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336:1106–10.

Umscheid CA Agarwal RK Brennan PJ ; Healthcare Infection Control Practices Advisory Committee. Updating the guideline development methodology of the Healthcare Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 2010; 38:264–73.

Centers for Disease Control and Prevention (US). Solid organ transplantation and the probability of transmitting HIV, HBV, or HCV: a systematic review to support an evidence-based guideline. 2010 [cited 2013 Jan 25]. Available from: URL: http://stacks.cdc.gov/view/cdc/12164/

42 U.S.C. §§273, 274.

42 C.F.R Part 121.

42 U.S.C. §274(b)(2)(E).

42 U.S.C. §273(b)(3)(C).

42 C.F.R. Part 121.6.

42 C.F.R. Part 121.4.

Metzger RA Delmonico FL Feng S Port FK Wynn JJ Merion RM . Expanded criteria donors for kidney transplantation. Am J Transplant 2003; 3(Suppl 4):114–25.

Health Resources and Services Administration (US). Organ Procurement and Transplantation Network. Policy 4: identification of transmissible diseases in organ recipients [cited 2012 Aug 15]. Available from: URL: http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp

Health Resources and Services Administration (US). Organ Procurement and Transplantation Network. Policy 2: minimum procurement standards for an organ procurement organization (OPO) [cited 2012 Aug 15]. Available from: URL: http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp

Ison MG Hager J Blumberg E Burdick J Carney K Cutler J Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009; 9:1929–35.

Fiebig EW Wright DJ Rawal BD Garrett PE Schumacher RT Peddada L Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871–9.

Glynn SA Wright DJ Kleinman SH Hirschkorn D Tu Y Heldebrant C Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005; 45:994–1002.

Haase AT . Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005; 5:783–92.

Kleinman SH Lelie N Busch MP . Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49:2454–89.

Busch MP Glynn SA Wright DJ Hirschkorn D Laycock ME McAuley J Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Transfusion 2005; 45:1853–63.

Weber B Berger A Rabenau H Doerr HW . Evaluation of a new combined antigen and antibody human immunodeficiency virus screening assay, VIDAS HIV DUO Ultra. J Clin Microbiol 2002; 40:1420–6.

Ly TD Ebel A Faucher V Fihman V Laperche S . Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods 2007; 143:86–94.

Perry KR Ramskill S Eglin RP Barbara JA Parry JV . Improvement in the performance of HIV screening kits. Transfus Med 2008; 18:228–40.

Kleinman SH Busch MP . Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006; 36 Suppl 1:S23–9.

Ellingson K Seem D Nowicki M Strong DM Kuehnert MJ ; Organ Procurement Organization Nucleic Acid Testing Yield Project Team. Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States. Am J Transplant 2011; 11:1201–8.

Health Resources and Services Administration (US). Organ Procurement and Transplantation Network. Policy 12: living donation [cited 2013 Jan 20]. Available from: URL: http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp

Kucirka LM Alexander C Namuyinga R Hanrahan C Montgomery RA Segev DL . Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs. Am J Transplant 2009; 9:620–8.

Ison MG Stosor V . Transplantation of high-risk donor organs: a survey of US solid organ transplant center practices as reported by transplant infectious diseases physicians. Clin Transplant 2009; 23:866–73.

Humar A Morris M Blumberg E Freeman R Preiksaitis J Kiberd B Nucleic acid testing (NAT) of organ donors: is the “best” test the right test? A consensus conference report. Am J Transplant 2010; 10:889–99.

Hidalgo G Tejani C Clayton R Clements P Distant D Vyas S Factors limiting the rate of living-related kidney donation to children in an inner city setting. Pediatr Transplant 2001; 5:419–24.

Renz JF Mudge CL Heyman MB Tomlanovich S Kingsford RP Moore BJ Donor selection limits use of living-related liver transplantation. Hepatology 1995; 22(4 Pt 1):1122–6.

Domen RE Yen-Lieberman B Nelson KA Chua J Sholtis W Tyus H Use of an HBV-DNA hybridization assay in the evaluation of equivocal hepatitis B virus tests in solid organ donors. Prog Transplant 2000; 10:42–6.

Richards PS Nelson KA Frazier OH Radovancevic B Van Buren C Young JB . Why referred potential heart donors aren't used. Tex Heart Inst J 1993; 20:218–22.

Shah G Demetris AJ Irish W Scheffel J Mimms L Van Thiel DH . Frequency and severity of HCV infection following orthotopic liver transplantation. Effect of donor and recipient serology for HCV using a second generation ELISA test. J Hepatol 1993; 18:279–83.

Vincenti F Lake J Wright T Kuo G Weber P Stempel C . Nontransmission of hepatitis C from cadaver kidney donors to transplant recipients. Transplantation 1993; 55:674–5.

Pereira BJ Milford EL Kirkman RL Levey AS . Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325:454–60.

Pereira BJ Milford EL Kirkman RL Quan S Sayre KR Johnson PJ Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 1992; 327:910–5.

Pereira BJ Milford EL Kirkman RL Quan S Sayre KR Johnson PJ Liver disease and HCV infection after transplantation of organs from hepatitis C antibody positive donors. Transplant Proc 1993; 25(1 Pt 2):1458–9.

Pereira BJ Wright TL Schmid CH Bryan CF Cheung RC Cooper ES Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study. Kidney Int 1994; 46:886–92.

Roth D Fernandez JA Babischkin S De Mattos A Buck BE Quan S Detection of hepatitis C virus infection among cadaver organ donors: evidence for low transmission of disease. Ann Intern Med 1992; 117:470–5.

Roth D Fernandez JA Babischkin S De Mattos A Buck BE Quan S Transmission of hepatitis C virus with solid organ transplantation: incidence and clinical significance. Transplant Proc 1993; 25(1 Pt 2):1476–7.

Shah G Demetris AJ Gavaler JS Lewis JH Todo S Starzl TE Incidence, prevalence, and clinical course of hepatitis C following liver transplantation. Gastroenterology 1992; 103:323–9.

Zou S Dodd RY Stramer SL Strong DM ; Tissue Safety Study Group. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 2004; 351:751–9.

Subpopulation estimates from the HIV Incidence Surveillance System—United States, 2006. MMWR Morb Mortal Wkly Rep 2008; 57(36):985–9.

Hall HI Song R Rhodes P Prejean J An Q Lee LM Estimation of HIV incidence in the United States. JAMA 2008; 300:520–9.

Daniels D Grytdal S Wasley A . Surveillance for acute viral hepatitis—United States, 2007. MMWR Surveill Summ 2009; 58(3):1–27.

Centers for Disease Control and Prevention (US). Disease burden from viral hepatitis A, B, and C in the United States [cited 2009 Jun 4]. Available from: URL: http://www.cdc.gov/hepatitis/PDFs/disease_burden.pdf

Weinbaum CM Williams I Mast EE Wang SA Finelli L Wasley A Recommendations for identification and public health management of people with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57(RR-8):1–20.

Armstrong GL Wasley A Simard EP McQuillan GM Kuhnert WL Alter MJ . The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705–14.

HIV prevalence estimates—United States, 2006. MMWR Morb Mortal Wkly Rep 2008; 57(39):1073–6.

Loss GE Jr Mason AL Nair S Blazek J Farr G Guo L Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl 2003; 9:1258–64.

Prieto M Gomez MD Berenguer M Cordoba J Rayon JM Pastor M De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7:51–8.

Dickson RC Everhart JE Lake JR Wei Y Seaberg EC Wiesner RH Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113:1668–74.

Yu AS Vierling JM Colquhoun SD Arnaout WS Chan CK Khanafshar E Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 7:513–7.

Roque-Afonso AM Feray C Samuel D Simoneau D Roche B Emile JF Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002; 50:95–9.

Dodson SF Bonham CA Geller DA Cacciarelli TV Rakela J Fung JJ . Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68:1058–61.

Uemoto S Inomata Y Sannomiya A Koshiba T Kurokawa T Takatsuki M Posttransplant hepatitis B infection in liver transplantation with hepatitis B core antibody-positive donors. Transplant Proc 1998; 30:134–5.

Uemoto S Sugiyama K Marusawa H Inomata Y Asonuma K Egawa H Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65:494–9.

Kiuchi T Tanaka K . Living-related donor liver transplantation: status quo in Kyoto, Japan. Transplant Proc 1998; 30:687–91.

Katsurada A Marusawa H Uemoto S Kaburagi A Tanaka K Chiba T . Circulating antibody to hepatitis B core antigen does not always reflect the latent hepatitis B virus infection in the liver tissue. Hepatol Res 2003; 25:105–14.

Kadian M Hawkins L Nespral J Schwartz ME Miller CM . Use of hepatitis B core antibody-positive multiorgan donors. J Transpl Coord 1994; 4:57–9.

Montalti R Nardo B Bertelli R Beltempo P Puviani L Vivarelli M Donor pool expansion in liver transplantation. Transplant Proc 2004; 36:520–2.

De Feo TM Grossi P Poli F Mozzi F Messa P Minetti E Kidney transplantation from anti-HBc+ donors: results from a retrospective Italian study. Transplantation 2006; 81:76–80.

De Feo TM Poli F Mozzi F Moretti MP Scalamogna M . Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transplant Proc 2005; 37:1238–9.

Holt D Thomas R Van Thiel D Brems JJ . Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002; 137:572–5.

Donataccio D Roggen F De Reyck C Verbaandert C Bodeus M Lerut J . Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int 2006; 19:38–43.

Suehiro T Shimada M Kishikawa K Shimura T Soejima Y Yoshizumi T Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int 2005; 25:1169–74.

Fabrega E Garcia-Suarez C Guerra A Orive A Casafont F Crespo J Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 2003; 9: 916–20.

Nery JR Nery-Avila C Reddy KR Cirocco R Weppler D Levi DM Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003; 75:1179–86.

Wachs ME Amend WJ Ascher NL Bretan PN Emond J Lake JR The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation 1995; 59:230–4.

Castells L Vargas V Rodriguez F Allende H Buti M Sanchez-Avila JF Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl 2002; 8:892–900.

Loss GE Mason AL Blazek J Dick D Lipscomb J Guo L Transplantation of livers from HBc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results. Clin Transplant 2001;15 Suppl 6:55–8.

Madayag RM Johnson Lb Bartlett ST Schweitzer EJ Constantine NT McCarter RJ Jr Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997; 64:1781–6.

Veroux M Puliatti C Gagliano M Cappello D Macarone M Vizcarra D Use of hepatitis B core antibody-positive donor kidneys in hepatitis B surface antibody-positive and -negative recipients. Transplant Proc 2005; 37:2574–5.

Fong TL Bunnapradist S Jordan SC Cho YW . Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of United Network for Organ Sharing database between 1994 and 1999. Transplantation 2002; 73:85–9.

Satterthwaite R Ozgu I Shidban H Aswad S Sunga V Zapanta R Jr Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors. Transplantation 1997; 64:432–5.

Akalin E Ames S Sehgal V Murphy B Bromberg JS . Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas transplantation. Clin Transplant 2005; 19:364–6.

Miedouge M Rostaing L Mansuy JM Sandres-Saune K Boudet F Izopet J . Screening for hepatitis B virus DNA in serum of organ donors and renal transplant recipients. Eur J Clin Microbiol Infect Dis 2003; 22:246–8.

Pinney SP Cheema FH Hammond K Chen JM Edwards NM Mancini D . Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies. J Heart Lung Transplant 2005; 24:34–7.

Ko WJ Chou NK Hsu RB Chen YS Wang SS Chu SH Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area. J Heart Lung Transplant 2001; 20:865–75.

Wang SS Chou NK Ko WJ Yu HY Chen YS Hsu RB Heart transplantation using donors positive for hepatitis. Transplant Proc 2004; 36:2371–3.

Blanes M Gomez D Cordoba J Almenar L Gobernado M Lopez-Aldeguer J Is there any risk of transmission of hepatitis B from heart donors hepatitis B core antibody positive? Transplant Proc 2002; 34:61–2.

Hartwig MG Patel V Palmer SM Cantu E Appel JZ Messier RH Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation. Transplantation 2005; 80:320–5.

Everhart JE Wei Y Eng H Charlton MR Persing DH Wiesner RH Recurrent and new hepatitis C virus infection after liver transplantation [published erratum appears in Hepatology 1999;30:1110]. Hepatology 1999; 29:1220–6.

Abbott KC Lentine KL Bucci JR Agodoa LY Koff JM Holtzmuller KC Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 2004; 15:3166–74.

Bucci JR Lentine KL Agodoa LY Peters TG Schnitzler MA Abbott KC . Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS/UNOS database. Clin Transpl 2004:51–61.

Rozental R Bicans J Shevelev V Trushkov S Amerika D . Kidney transplantation from hepatitis C virus positive donors. Transplant Proc 2002; 34:2581.

Tokumoto T Tanabe K Sonda K Koga S Gouya N Yagisawa T Effect of interferon (IFN-alpha) for prevention of hepatitis C transmission from a seropositive donor to a seronegative recipient in renal transplantation. Transplant Proc 1996; 28:1503–4.

Wreghitt TG Gray JJ Allain JP Poulain J Garson JA Deaville R Transmission of hepatitis C virus by organ transplantation in the United Kingdom. J Hepatol 1994; 20:768–72.

Mendez R Aswad S Bogaard T Khetan U Asai P Martinez A Donor hepatitis C antibody virus testing in renal transplantation. Transplant Proc 1993; 25(1 Pt 2):1487–90.

Aswad S Mendez R Weingart RG Mendez R . Expanding organ availability by using hepatitis C antibody positive donors. Transplant Proc 1993; 25:2270–1.

Tesi RJ Waller K Morgan CJ Delaney S Elkhammas EA Henry ML Transmission of hepatitis C by kidney transplantation—the risks. Transplantation 1994; 57:826–31.

Tesi RJ Waller MK Morgan CJ Delaney S Elkhammas EA Henry ML Use of low-risk HCV-positive donors for kidney transplantation. Transplant Proc 1993; 25(1 Pt 2):1472–3.

Preiksaitis JK Cockfield SM Fenton JM Burton NI Chui LW . Serologic responses to hepatitis C virus in solid organ transplant recipients. Transplantation 1997; 64:1775–80.

File E Mehra M Nair S Dumas-Hicks D Perrillo R . Allograft transmission of hepatitis C virus infection from infected donors in cardiac transplantation. Transplantation 2003; 76:1096–100.

Haji SA Starling RC Avery RK Mawhorter S Tuzcu EM Schoenhagen P Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 2004; 23:277–83.

Shea KJ Sopko NA Ludrosky K Hoercher K Smedira NG Taylor DO The effect of a donor's history of active substance on outcomes following orthotopic heart transplantation. Eur J Cardiothorac Surg 2007; 31:452–6.

Ong JP Barnes DS Younossi ZM Gramlich T Yen-Lieberman B Goormastic M Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999; 30:1293–8.

Gudmundsson GS Malinowska K Robinson JA Pisani BA Mendez JC Foy BK Five-year follow-up of hepatitis C-naive heart transplant recipients who received hepatitis C-positive donor hearts. Transplant Proc 2003; 35:1536–8.

Marelli D Bresson J Laks H Kubak B Fonarow G Tsai FC Hepatitis C-positive donors in heart transplantation. Am J Transplant 2002; 2:443–7.

McQuillan GM Kruszon-Moran D Kottiri BJ Kamimoto LA Lam L Cowart MF Prevalence of HIV in the US household population: the National Health and Nutrition Examination Surveys, 1988 to 2002. J Acquir Immune Defic Syndr 2006; 41:651–6.

Nguyen TQ Gwynn RC Kellerman SE Begier E Garg RK Pfeiffer MR Population prevalence of reported and unreported HIV and related behaviors among the household adult population in New York City, 2004. AIDS 2008; 22:281–7.

Mehta SD Hall J Greenwald JL Cranston K Skolnik PR . Patient risks, outcomes, and costs of voluntary HIV testing at five testing sites within a medical center. Public Health Rep 2008; 123:608–17.

Sanchez P Heck E Rivera C Sanchez A Cavanagh HD . Risk factors for infectious disease in corneal transplant screening. Eye Contact Lens 2006; 32:124–7.

Alpert PL Shuter J DeShaw MG Webber MP Klein RS . Factors associated with unrecognized HIV-1 infection in an innercity emergency department. Ann Emerg Med 1996; 28:159–64.

Fischer LR Tope DH Conboy KS Hedblom BD Ronberg E Shewmake DK Screening for hepatitis C virus in a health maintenance organization. Arch Intern Med 2000; 160:1665–73.

McQuillan GM Coleman PJ Kruszon-Moran D Moyer LA Lambert SB Margolis HS . Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89:14–8.

Hwang LY Kramer JR Troisi C Bull L Grimes CZ Lyerla R Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. Hepatology 2006; 44:341–51.

Kaur S Rybicki L Bacon BR Gollan JL Rustgi VK Carey WD . Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results of the National Hepatitis Screening Survey. Hepatology 1996; 24:979–86.

Tabibian JH Wirshing DA Pierre JM Guzik LH Kisicki MD Danovitch I Hepatitis B and C among veterans on a psychiatric ward. Dig Dis Sci 2008; 53:1693–8.

Butterfield MI Bosworth HB Stechuchak KM Frothingham R Bastian LA Meador KG Racial differences in hepatitis B and hepatitis C and associated risk behaviors in veterans with severe mental illness. J Natl Med Assoc 2004; 96:43–52.

Butterfield CR Shockley M San MG Rosa C . Routine screening for hepatitis B in an obstetric population. Obstet Gynecol 1990; 76:25–7.

Alter MJ Coleman PJ Alexander WJ Kramer E Miller JK Mandel E Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989; 262:1201–5.

Murphy EL Bryzman SM Glynn SA Ameti DI Thomson RA Williams AE Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology 2000; 31:756–62.

Hand WL Vasquez Y . Risk factors for hepatitis C on the Texas-Mexico border. Am J Gastroenterol 2005; 100:2180–5.

Orton SL Stramer SL Dodd RY Alter MJ . Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. Transfusion 2004; 44:275–81.

Conry-Cantilena C VanRaden M Gibble J Melpolder J Shakil AO Viladomiu L Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334:1691–6.

Nguyen MT Herrine SK Laine CA Ruth K Weinberg DS . Description of a new hepatitis C risk assessment tool. Arch Intern Med 2005; 165:2013–8.

Gasink LB Blumberg EA Localio AR Desai SS Israni AK Lautenbach E . Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA 2006; 296:1843–50.

Zetola NM Kaplan B Dowling T Jensen T Louie B Shahkarami M Prevalence and correlates of unknown HIV infection among patients seeking care in a public hospital emergency department. Public Health Rep 2008;123 Suppl 3:41–50.

Turner SB Kunches LM Gordon KF Travers PH Mueller NE . Occupational exposure to human immunodeficiency virus (HIV) and hepatitis B virus (HBV) among embalmers: a pilot seroprevalence study. Am J Public Health 1989; 79:1425–6.

Lin SY Chang ET So SK . Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology 2007; 46:1034–40.

Hann HW Hann RS Maddrey WC . Hepatitis B virus infection in 6,130 unvaccinated Korean-Americans surveyed between 1988 and 1990. Am J Gastroenterol 2007; 102:767–72.

Lee H Levin MJ Kim F Warner A Park W . Hepatitis B infection among Korean Americans in Colorado: evidence of the need for serologic testing and vaccination. Hepatitis Monthly 2008; 8:91–6.

Luban NL Colvin CA Mohan P Alter HJ . The epidemiology of transfusion-associated hepatitis C in a children's hospital. Transfusion 2007; 47:615–20.

Murphy EL Bryzman S Williams AE Co-Chien H Schreiber GB Ownby HE Demographic determinants of hepatitis C virus seroprevalence among blood donors. JAMA 1996; 275:995–1000.

McGinn T O'Connor-Moore N Alfandre D Gardenier D Wisnivesky J . Validation of a hepatitis C screening tool in primary care. Arch Intern Med 2008; 168:2009–13.

Barbe F Klein M Badonnel Y . Early detection of antibodies to human immunodeficiency virus 1 by a third-generation enzyme immunoassay. A comparative study with the results of second-generation immunoassays and western blot. Ann Biol Clin (Paris) 1994; 52:341–5.

Owen SM Yang C Spira T Ou CY Pau CP Parekh BS Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol 2008; 46:1588–95.

Food and Drug Administration (US). Vaccines, blood & biologics. Genetic systems HIV-1/HIV-2 plus O EIA [cited 2009 Sep 29]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm091151.htm

Food and Drug Administration (US). Vaccines, blood & biologics. ABBOTT HIVAB HIV-1/HIV-2 (rDNA) EIA [cited 2009 Sep 29]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm091149.htm

Vargo J Smith K Knott C Wang S Fang C McDonough S Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. Transfusion 2002; 42:876–85.

Jackson JB Smith K Knott C Korpela A Simmons A Piwowar-Manning E Sensitivity of the Procleix HIV-1/HCV assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA in a high-risk population. J Clin Microbiol 2002; 40:2387–91.

Candotti D Richetin A Cant B Temple J Sims C Reeves I Evaluation of a transcription-mediated amplification-based HCV and HIV-1 RNA duplex assay for screening individual blood donations: a comparison with a minipool testing system. Transfusion 2003; 43:215–25.

Kolk DP Dockter J Linnen J Ho-Sing-Loy M Gillotte-Taylor K McDonough SH Significant closure of the human immunodeficiency virus type 1 and hepatitis C virus preseroconversion detection windows with a transcription-mediated-amplification-driven assay. J Clin Microbiol 2002; 40:1761–6.

Yang Y Wisbeski MH Mendoza M Dorf S Xu D Nguyen M Performance characteristics of the AmpliScreen HIV-1 test, an assay designed for screening plasma mini-pools. Biologicals 1999; 27: 315–23.

Food and Drug Administration (US). Vaccines, blood & biologics. Procleix HIV-1/HCV assay [cited 2009 Sep 17]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm092022.htm

Food and Drug Administration (US). Vaccines, blood & biologics. COBAS AmpliScreen HIV-1 Test [cited 2009 Sep 17]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm093493.htm

Bamaga MS Bokhari FF Aboud AM Al-Malki M Alenzi FQ . Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations. Saudi Med J 2006; 27:781–7.

Aghokeng AF Ewane L Awazi B Nanfack A Delaporte E Peeters M Evaluation of four simple/rapid assays and two fourth-generation ELISAs for the identification of HIV infection on a serum panel representing the HIV-1 group M genetic diversity in Cameroon. J Acquir Immune Defic Syndr 2004; 37:1632–40.

Bourlet T Pretis C Pillet S Lesenechal M Piche J Pozzetto B . Comparative evaluation of the VIDAS HIV DUO Ultra assay for combined detection of HIV-1 antigen and antibodies to HIV. J Virol Methods 2005; 127:165–7.

Kwon JA Yoon SY Lee CK Lim CS Lee KN Sung HJ Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays. J Virol Methods 2006; 133:20–6.

Ly TD Servant-Delmas A Bagot S Gonzalo S Ferey MP Ebel A Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol 2006; 44:2321–6.

Ly TD Laperche S Brennan C Vallari A Ebel A Hunt J Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Methods 2004; 122:185–94.

Sickinger E Stieler M Kaufman B Kapprell HP West D Sandridge A Multicenter evaluation of a new, automated enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies and antigen. J Clin Microbiol 2004; 42:21–9.

Weber B Gürtler L Thorstensson R Michl U Mühlbacher A Burgisser P Multicenter evaluation of a new automated fourth-generation human immunodeficiency virus screening assay with a sensitive antigen detection module and high specificity. J Clin Microbiol 2002; 40:1938–46.

Saville RD Constantine NT Cleghorn FR Jack N Bartholomew C Edwards J Fourth-generation enzyme-linked immunosorbent assay for the simultaneous detection of human immunodeficiency virus antigen and antibody. J Clin Microbiol 2001; 39:2518–24.

Seyoum E Wolday D Mekonen T Girma M Meselle T Källander C Alternative approach to blood screening using the ExaVir reverse transcriptase activity assay. Curr HIV Res 2005; 3:371–6.

Delieu E Donovan LG Perry KR Parry JV . Murex HIV Ag/Ab combination EIA (product code: GE41/GE42). London: Medical Devices Agency, Microbiological Diagnostics Assessment Service; 2001. MDA Evaluation Report No. 01123.

Diepersloot RJ van Zantvlietvan OY Gleaves CA . Comparison of a chemiluminescent immunoassay with two microparticle enzyme immunoassays for detection of hepatitis B virus surface antigen. Clin Diagn Lab Immunol 2000; 7:865–6.

Huzly D Schenk T Jilg W Neumann-Haefelin D . Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol 2008; 46:1298–306.

Food and Drug Administration (US). Vaccines, blood & biologics. Genetic Systems HBsAg EIA 3.0 [cited 2009 Sep 29]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm085808.htm

Food and Drug Administration (US). Medical devices. AxSYM HBsAg Assay—P050049 [cited 2009 Sep 29]. Available from: URL: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm078174.htm

Food and Drug Administration (US). Medical devices. ADVIA Centaur HBsAg ReadyPack Reagents, ADVIA Centaur HBsAg Confirmatory ReadyPack Reagents, and ADVIA Centaur HBsAg Quality Control Material—P030049 [cited 2009 Sep 29]. Available from: URL: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm078604.htm

Food and Drug Administration (US). Vaccines, blood & biologics. COBAS AmpliScreen HBV Test [cited 2009 Sep 17]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm077872.htm

Ortho Clinical Diagnostics. Donor screening. Genetic Systems HBsAg EIA 3.0. 2006 [cited 2009 Sep 17]. Available from: URL: http://www.orthoclinical.com/enus/ProductInformation/TransfusionMedicine/DonorScreening/Pages/ScreeningAssays.aspx

Food and Drug Administration (US). Medical devices. ADVIA Centaur HBc Total ReadyPack Reagents, ADVIA Centaur HBc Total Quality Control Materials—P040004 [cited 2009 Sep 29]. Available from: URL: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm078871.htm

Food and Drug Administration (US). Medical devices. Bayer ADVIA Centaur HCV Assay—P030056 [cited 2009 Sep 29]. Available from: URL: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm079236.htm

Kleinman SH Strong DM Tegtmeier GG Holland PV Gorlin JB Cousins C Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion 2005; 45:1247–57.

Romano L Velati C Baruffi L Fomiatti L Colucci G Zanetti AR Multicenter evaluation of a semiautomated, standardized assay for detection of hepatitis B virus DNA in blood donations. J Clin Microbiol 2005; 43:2991–3.

Anderson SC Hathaway T Kuramoto IK Holland PV Gilcher R Koch T Comparison of two second-generation anti-hepatitis C virus ELISA on 21431 US blood donor samples. J Viral Hepat 1995; 2:55–61.

Laycock KA Essary LR Delaney S Kuhns MC Pepose JS . A critical evaluation of hepatitis C testing of cadaveric corneal donors. Cornea 1997; 16:146–50.

Leon P Lopez JA Domingo C Echevarria JM . Evaluation of laboratory assays for screening antibody to hepatitis C virus. Transfusion 1993; 33:268–70.

Vrielink H Zaaijer HL Reesink HW Lelie PN van der Poel CL . Comparison of two anti-hepatitis C virus enzyme-linked immunosorbent assays. Transfusion 1995; 35:601–4.

Vrielink H Zaaijer HL Reesink HW van der Poel CL Cuypers HT Lelie PN . Sensitivity and specificity of three third-generation anti-hepatitis C virus ELISAs. Vox Sang 1995; 69:14–7.

Kita M Deguchi M Kagita M Yoshioka N Kobayashi E Watanabe M Clinical utility and characteristics of nine anti-HCV antibody screening reagents used in Japan. Clin Lab 2009; 55:9–22.

Denoyel G van Helden J Bauer R Preisel-Simmons B . Performance of a new hepatitis C assay on the Bayer ADVIA Centaur Immunoassay System. Clin Lab 2004; 50:75–82.

Galel SA Strong DM Tegtmeier GE Holland PV Kuramoto IK Kemper M Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays. Transfusion 2002; 42:1507–13.

Barrera JM Francis B Ercilla G Nelles M Achord D Darner J Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995; 68:15–8.

Food and Drug Administration (US). Vaccines, blood & biologics. COBAS AmpliScreen HCV Test [cited 2009 Sep 17]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm173197.htm

Katsoulidou AS Moschidis ZM Gialeraki RE Paraskevis DN Sypsa VA Lazanas MC Clinical evaluation of an HIV-1 and HCV assay and demonstration of significant reduction of the HCV detection window before seroconversion. Transfusion 2004; 44:59–66.

Laperche S Elghouzzi MH Morel P Asso-Bonnet M Le Marrec N Girault A Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? Transfusion 2005; 45:1965–72.

Laperche S Le Marrec N Girault A Bouchardeau F Servant-Delmas A Maniez-Montreuil M Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J Clin Microbiol 2005; 43:3877–83.

Dean L Perry K Nichols T . Evaluation of MONOLISA HCV Ag-Ab ULTRA. London: Health Protection Agency, Centre for Infections; 2006.

Zucker K Cirocco R Roth D Olson L Burke GW Nery J Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation. Transplantation 1994; 57:832–40.

Roth D Zucker K Cirocco R Burke G Olson L Esquenazi V Transmission of hepatitis C virus by kidney transplantation: impact of perfusion techniques and course of viremia post transplant. Pediatr Nephrol 1995; 9 Suppl:S29–34.

Abbott KC Lentine KL Bucci JR Agodoa LY Peters TG Schnitzler MA . The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004; 4:2032–7.

Lai MK Huang CC Chu SH Chuang CK Chen CS Chen HW . The outcome of kidney transplantation from HBsAg-positive donors. Asian J Surg 1994; 17:340–3.

Lai MK Chang KS Chueh SC Huang CC Chen SC Chu SH . Kidney transplantation from hepatitis B surface antigen (HBsAg)-positive donors: changes of relative HBV genomic copy number after transplantation. Transplant Proc 1996; 28:1518–9.

Chen JB Hsieh H Hsu KT Chen CH . Impact of donor hepatitis B antigenemia on renal allograft in hepatitis B recipients. Transplant Proc 1996; 28:1490–2.

Saab S Chang AJ Comulada S Geevarghese SK Anselmo RD Durazo F Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl 2003; 9:1053–61.

Bucci JR Matsumoto CS Swanson SJ Agodoa LY Holtzmuller KC Peters TG Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002; 13:2974–82.

Abbott KC Bucci JR Matsumoto CS Swanson SJ Agodoa LY Holtzmuller KC Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14:2908–18.

Velidedeoglu E Desai NM Campos L Olthoff KM Shaked A Nunes F Effect of donor hepatitis C on liver graft survival. Transplant Proc 2001; 33:3795–6.

Velidedeoglu E Desai NM Campos L Olthoff KM Shaked A Nunes F The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 2002; 73:582–7.

Morales JM Campistol JM Castellano G Andres A Colina F Fuertes A Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int 1995; 47:236–40.

Woodside KJ Ishihara K Theisen JE Early MG Covert LG Hunter GC Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-yr outcome. Clin Transplant 2003; 17:433–7.

Ali MK Light JA Barhyte DY Sasaki TM Currier CB Jr Grandas O Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation 1998; 66:1694–7.

Kasprzyk T Kwiatkowski A Wszola M Ostrowski K Danielewicz R Domagala P Long-term results of kidney transplantation from HCV-positive donors. Transplant Proc 2007; 39:2701–3.

Salizzoni M Lupo F Zamboni F Franchello A Lavezzo B Cerutti E Outcome of patients transplanted with liver from hepatitis C positive donors. Transplant Proc 2001; 33:1507–8.

Testa G Goldstein RM Netto G Abbasoglu O Brooks BK Levy MF Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation 1998; 65:925–9.

Marroquin CE Marino G Kuo PC Plotkin JS Rustgi VK Lu AD Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl 2001; 7:762–8.

Vargas HE Laskus T Wang LF Lee R Radkowski M Dodson F Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999; 117:149–53.

Mandal AK Kraus ES Samaniego M Rai R Humphreys SL Ratner LE Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant 2000; 14(4 Pt 2):391–6.

Schweitzer EJ Perencevich En Philosophe B Bartlett ST . Estimated benefits of transplantation of kidneys from donors at increased risk for HIV or hepatitis C infection. Am J Transplant 2007; 7:1515–25.

Freeman RB Cohen JT . Transplantation risks and the real world: what does “high risk” really mean? Am J Transplant 2009; 9:23–30.

Organ Procurement and Transplantation Network. 2007 annual report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients [cited 2013 Apr 6]. Available from: URL: http://www.ustransplant.org/annual_reports/current/ar_archives.htm

Fishman JA . Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601–14.

Fishman JA Greenwald MA Kuehnert MJ . Enhancing transplant safety: a new era in the microbiologic evaluation of organ donors? Am J Transplant 2007; 7:2652–4.

Kahneman D Tversky A , editors. Choices, values and frames. New York: Cambridge University Press; 2000.

Halpern SD Shaked A Hasz RD Caplan AL . Informing candidates for solid-organ transplantation about donor risk factors. N Engl J Med 2008; 358:2832–7.

Kucirka LM Namuyinga R Hanrahan C Montgomery RA Segev DL . Formal policies and special informed consent are associated with higher provider utilization of CDC high-risk donor organs. Am J Transplant 2009; 9:629–35.

Updated U .S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001; 50(RR-11):1–52.

Panlilio AL Cardo DM Grohskopf L Heneine W Ross CS . Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2005; 54(RR-9):1–17.

Smith DK Grohskopf LA Black RJ Auerbach JD Veronese F Struble KA Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005; 54(RR-2):1–20.

Occupational Safety and Health Administration (US). Bloodborne pathogens. Post-exposure follow-up (29 C.F.R. 1910.1030) [cited 2010 Sep 2]. Available from: URL: http://www.osha.gov/SLTC/etools/hospital/hazards/bbp/bbp.html#PostExposureFollow-up

Ison MG . The epidemiology and prevention of donor-derived infections. Adv Chronic Kidney Dis 2009; 16:234–41.

Tugwell BD Patel PR Williams IT Hedberg K Chai F Nainan OV Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Ann Intern Med 2005; 143:648–54.

Ison MG Friedewald JJ . Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl 2009; 15:561.

Busch MP Wilber JC Johnson P Tobler L Evans CS . Impact of specimen handling and storage on detection of hepatitis C virus RNA. Transfusion 1992; 32:420–5.

Halfon P Khiri H Gerolami V Bourliere M Feryn JM Reynier P Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA. J Hepatol 1996; 25:307–11.

Gessoni G Barin P Valverde S Giacomini A Di Natale C Orlandini E Biological qualification of blood units: considerations about the effects of sample's handling and storage on stability of nucleic acids. Transfus Apher Sci 2004; 30:197–203.

Strong DM Nelson K Pierce M Stramer SL . Preventing disease transmission by deceased tissue donors by testing blood for viral nucleic acid. Cell Tissue Bank 2005; 6:255–62.

Eastlund T . Hemodilution due to blood loss and transfusion and reliability of cadaver tissue donor infectious disease testing. Cell Tissue Bank 2000; 1:121–7.

Rose C Mohr J Gross M Lee S . Hemodilution—an overview of current Canadian practices. Cell Tissue Bank 2001; 2:41–4.

Busch MP Kleinman SH Tobler LH Kamel HT Norris PJ Walsh I Virus and antibody dynamics in acute West Nile virus infection. J Infect Dis 2008; 198:984–93.

Comanor L Holland P . Hepatitis B virus blood screening: unfinished agendas [published erratum appears in Vox Sang 2007;92:278]. Vox Sang 2006; 91:1–12.

Preiksaitis JK Sandhu J Strautman M . The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center. Transfusion 2002; 42:396–402.

Dow BC Yates P Galea G Munro H Buchanan I Ferguson K . Hepatitis B vaccinees may be mistaken for confirmed hepatitis B surface antigen-positive blood donors. Vox Sang 2002; 82:15–7.